Pair Name | Fisetin, Cisplatin | ||
Phytochemical Name | Fisetin (PubChem CID: 5281614 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Drug Name | Cisplatin |
Adverse Reactions | Myelosuppression, dry mouth and throat, fever, dry stools. This was inferred hot nature anticancer drug. |
Recommendations | Cold: Anemarrhena asphodeloides; Urena lobataL; Artemisia scoparia; Swertia mussotii; Swertia pseudochinensis; Gentiana manshurica; Gossampinus malabarica; Pyrrosia sheareri; Pyrrosia sheareri; Iris domestica; Gentiana scabra; Pyrrosia sheareri; Pyrrosia petiolosa |
Reference | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. ref_link |
Pair Name | Fisetin, Cisplatin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
In Vitro Model | LL/2 (LLC1) | Malignant tumors of the mouse pulmonary system | Mus musculus (Mouse) | CVCL_4358 |
In Vivo Model | Female 6-weeks old C57BL/6J mice were used for anti-tumor evaluation. Lewis lung tumor fragments (about 30 mm3) were injected subcutaneously (s.c.) bilaterally into the flanks of the mice (day 1). | |||
Result | The combination index between liposomal fisetin and liposomal cisplatin on 3LL cell line after 24 h of exposure showed a clear synergism: CI = 0.7 for the co loaded liposomes and CI = 0.9 for the mixture of cisplatin loaded and fisetin loaded liposomes. The co-encapsulating formulation showed in vivo efficacy against an ectopic murine model of Lewis Lung carcinoma with a probable reduction in the toxicity of cisplatin through co-encapsulation with fisetin. |
No. | Title | Href |
---|---|---|
1 | Co-encapsulation of fisetin and cisplatin into liposomes: Stability considerations and in vivo efficacy on lung cancer animal model. Int J Pharm. 2024 Feb 15;651:123744. doi: 10.1016/j.ijpharm.2023.123744. | Click |